Overview
Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
Status:
Unknown status
Unknown status
Trial end date:
2015-05-01
2015-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To detect resistance gene from serially collected plasma DNA in non-small cell lung cancer harbouring EGFR activating mutation who are being treated with EGFR TKIs by using castPCR method.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Samsung Medical CenterCollaborator:
AstraZenecaTreatments:
Afatinib
Erlotinib Hydrochloride
Gefitinib
Criteria
Inclusion Criteria:- 1. Histologically confirmed NSCLC 2. Aged of or older than 20 years 3. ECOG
performance status 0-2 4. Adequate hematological, renal, hepatic function 5. Patients
with tumors harboring EGFR mutation (del 19 or L858R mutation) 6. Patient who are
about to be treated with EGFR TKI (gefitinib, erlotinib or other EGFR TKI) 7. At least
more than one measurable disease 8. Informed consent
Exclusion Criteria:
- 1. Active infection 2. Active bleeding